The incidence of cancer increases with age in both humans and laboratory animals. A clear understanding of the causes of the age-related increase in cancer incidence is needed to develop a strategy for primary cancer prevention.
Methods
We summarized the data available in the literature and our own experience in hormonal metabolic shifts in organisms and disturbances at tissue and cellular levels observed in natural aging and in different types of carcinogenesis in vivo.
Results
There are incongruent patterns of age-related distribution of tumors in different organs and tissues. Aging may increase or decrease the susceptibility of various tissues to initiation of carcinogenesis and usually facilitates promotion and progression of carcinogenesis. Aging may predispose to cancer by at least two mechanisms: tissue accumulation of cells in late stages of carcinogenesis and alterations in internal homeostasis, in particular, alterations in immune and endocrine system. Increased susceptibility to the effects of tumor promoters is found in both aged animals and aged humans, as predicted by the multistage model of carcinogenesis.
Conclusions
Aging is associated with a number of events at the molecular, cellular and physiologic levels that influence carcinogenesis and subsequent cancer growth. A clearer understanding of these events will help in predicting and treating cancer more effectively.
References
1.
AnisimovV.N.. Carcinogenesis and aging.Adv Cancer Res.1983; 40: 365–424.
DixD., CohenP.. On the role of aging in carcinogenesis.Anticancer Res.1999; 19: 723–726.
4.
ParkinD.M., BrayFl, DevesaS.S.. Cancer burden in the year 2000: the global picture.Eur J Cancer.2001; 37(suppl 8): S4–S66.
5.
BalducciL., ErshlerW.B.. Cancer and ageing: a nexus at several levels.Nat Rev Cancer.2005; 5: 655–662.
6.
AnisimovV.N., UkraintsevaS.V., YashinA.I.. Cancer in rodents: does it tell us about cancer in humans?Nat Rev Cancer.2005; 5: 807–819.
7.
PetoR., ParishS.E., GrayR.G.. There is no such thing as ageing, and cancer is not related to it. In: LikhachevA., AnisimovV., MontesanoR., eds. Age Related Factors in Carcinogenesis. IARC Scientific Publication No. 58. Lyon, France: International Agency for Research on Cancer; 1985: 43–53.
8.
AnisimovV.N.. The relationship between aging and carcinogenesis: a critical appraisal.Crit Rev Oncol Hematol.2003; 45: 277–304.
9.
MillerR.A.. Gerontology as oncology: research on aging as the key to the understanding of cancer.Cancer.1991; 68: 2496–2501.
10.
DilmanV.M.. Development, Aging, and Disease. A New Rationale for and Intervention Strategy.Chur, Switzerland: Harwood Acad Publ; 1994.
11.
SimpsonA.J.. A natural somatic mutation frequency and human carcinogenesis.Adv Cancer Res.1997; 71: 209–240.
12.
CampisiJ.. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors.Cell.2005; 120: 513–522.
13.
DePinhoR.A.. The age of cancer.Nature.2000; 408: 248–254.
14.
HarmanD.. Extending functional life span.Exp Gerontol.1998; 33: 95–112.
15.
HamiltonM.L., Van RemmenH., DrakeJ.A.. Does oxidative damage to DNA increase with age?Proc Natl Acad Sci U S A.2001; 98: 10469–10474. Epub 2001 Aug 21.
16.
von ZglinickiT., BurkleA., KirkwoodT.B.. Stress, DNA damage and ageing - an integrative approach.Exp Gerontol.2001; 36: 1049–1062.
17.
KawanishiS., HirakuY., OikawaS.. Mechanism of guanine-specific DNA damage by oxidative stress and its role in carcinogenesis and aging.Mutat Res.2001; 488: 65–76.
18.
SingerB., GrunbergerD.. Molecular Biology of Mutagens and Carcinogens.New York: Plenum Press; 1983.
19.
MorrisS.M.. The genetic toxicology of 5-bromodeoxyuridine in mammalian cells.Mutat Res.1991; 258: 161–188.
20.
WardJ.M., HennemanJ.R., OsipovaGYu,. Persistence of 5-bromo-2′-deoxyuridine in tissues of rats after exposure in early life.Toxicology.1991; 70: 345–352.
21.
AnisimovV.N.. The sole DNA damage induced by bromodeoxyuridine is sufficient for initiation of both aging and carcinogenesis in vivo.Ann N Y Acad Sci.1994; 719: 494–501.
22.
NapalkovN.P., AnisimovV.N., LikhachevA.J.. 5-Bromodeoxyuridine-induced carcinogenesis and its modification by persistent estrus syndrome, unilateral nephrectomy, and X-irradiation in rats.Cancer Res.1989; 49: 318–323.
23.
AnisimovV.N., OsipovaGYu. Effect of neonatal exposure to 5-bromo-2′-deoxyuridine on life span, estrus function and tumor development in rats: an argument in favor of the mutation theory of aging?Mutat Res.1992; 275: 97–110.
24.
MichishitaE., NakabayashiK., SuzukiT.. 5-Bromodeoxyuridine induces senescence-like phenomena in mammalian cells regardless of cell type or species.J Biochem (Tokyo).1999; 126: 1052–1059.
25.
SuzukiT., MinagawaS., MichishitaE.. Induction of senescence-associated genes by 5-bromodeoxyuridine in HeLa cells.Exp Gerontol.2001; 36: 465–474.
26.
MinagawaS., NakabayashiK., FujiiM.. Early BrdU-responsive genes constitute a novel class of senescence-associated genes in human cells.Exp Cell Res.2005; 304: 552–558. Epub 2004 Dec 15.
27.
AnisimovV.N.. Effect of aging and interval between primary and secondary treatment in carcinogenesis induced by neonatal exposure to 5-bromodeoxyuridine and subsequent administration of N-nitrosomethylurea in rats.Mutat Res.1995; 316: 173–187.
28.
ButovA.A., VolkovM.A., AnisimovV.N.. Mathematical and simulating model of accelerated aging induced by 5-bromo-2-deoxyuridine [in Russian].Adv Gerontol.2001; 8: 70–76.
29.
ShayJ.W., RoninsonI.B.. Hallmarks of senescence in carcinogenesis and cancer therapy.Oncogene.2004; 23: 2919–2933.
30.
CampisiJ.. Cancer, aging, and cellular senescence.In Vivo.2000; 14: 183–188.
31.
CampisiJ.. Cellular senescence and apoptosis: how cellular responses might influence aging phenotypes.Exp Gerontol.2003; 38: 5–11.
32.
DimriG.P., LeeX., BasileG.. A novel biomarker identifies senescent human cells in culture and in aging skin in vivo.Proc Natl Acad Sci U S A.1995; 92: 9363–9367.
33.
ParadisV., YoussefN., DargereD.. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas.Hum Pathol.2001; 32: 327–332.
34.
DimriG.P.. What has senescence got to do with cancer?Cancer Cell.2005; 7: 505–512.
35.
MishimaK., HandaJ.T., Aotaki-KeenA.. Senescence-associated beta-galactosidase histochemistry for the primate eye.Invest Ophthalmol Vis Sci.1999; 40: 1590–1593.
36.
KrtolicaA., ParrinelloS., LockettS.. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging.Proc Natl Acad Sci U S A.2001; 98: 12072–12077. Epub 2001 Oct 2.
37.
ChoiJ., ShendrikI., PeacockeM.. Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia.Urology.2000; 56: 160–166.
38.
VasileE., TomitaY., BrownL.F.. Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis.FASEB J.2001; 15: 458–466.
39.
CampisiJ., KimS.H., LimC.S.. Cellular senescence, cancer and aging: the telomere connection.Exp Gerontol.2001; 36: 1619–1637.
40.
ItahanaK., CampisiJ., DimriG.P.. Mechanisms of cellular senescence in human and mouse cells.Biogerontology.2004; 5: 1–10.
41.
KimS.H., KaminkerP., CampisiJ.. Telemeres, aging and cancer: in search of a happy ending.Oncogene.2002; 21: 503–511.
42.
SchmittC.A., FridmanJ.S., YangM.. A senescent program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy.Cell.2002; 109: 335–346.
43.
CristofaloV.J.. SA beta Gal staining: biomarker or delusion.Exp Gerontol.2005; 40: 836–838. Epub 2005 Sep 21.
44.
AnisimovV.N.. Effect of host age on tumor growth rate in rodents.Front Biosci.2006; 11: 412–422.
45.
MikhninA.E., BarchukA.S., WagnerR.I.. Kinetics of visual growth of skin melanoma.Russ Oncol J.2004; 2: 29–32.
46.
AnisimovV.N., ZhukovskayaN.V., LoktionovA.S.. Influence of host age on lung colony forming capacity of injected rat rhabdomyosarcoma cells.Cancer Lett.1988; 40: 77–82.
47.
AnisimovV.N., ZhukovskayaN.V., LoktionovA.S.. Host and donor age dependency of colony forming capacity of lung affine rat rhabdomyosarcoma RA-2 cells. Presented at the First International Conference on Tumor Microenvironment: Progression, Therapy, and Prevention. Tiberias, Israel. 1995: 6. Abstract.
48.
McCulloughK.D., ColemanW.B., SmithG.J.. Age-dependent regulation of the tumorigenic potential of neoplastically transformed rat liver epithelial cells by the liver microenvironment.Cancer Res.1994; 54: 3668–3671.
49.
BartkeA., ChandrashekarV., DominiciF.. Insulin-like growth factor 1 (IGF-1) and aging: controversies and new insights.Biogerontology.2003; 4: 1–8.
50.
FacchiniF.S., HuaN.W., ReavenG.M.. Hyperinsulinemia: the missing link among oxidative stress and age-related diseases?Free Radic Biol Med.2000; 29: 1302–1306.
51.
ColangeloL.A., GapsturS.M., GannP.H.. Colorectal cancer mortality and factors related to the insulin resistance syndrome.Cancer Epidemiol Biomarkers Prev.2002; 11: 385–391.
52.
DillinA., CrawfordD.K., KenyonC.. Timing requirements for insulin/IGF-1 signaling in C. elegans.Science.2002; 298: 830–834.
53.
RichardsJ.S., RussellD.L., OchsnerS.. Novel signaling pathways that control ovarian follicular development, ovulation, and luteinization.Recent Prog Horm Res.2002; 57: 195–220.
54.
HsiehC.C., DeFordJ.H., FlurkeyK.. Implications for the insulin signaling pathway in Snell dwarf mouse longevity: a similarity with the C. elegans longevity paradigm.Mech Ageing Dev.2002; 123: 1229–1244.
55.
HsiehC.C., DeFordJ.H., FlurkeyK.. Effects of the Pit1 mutation on the insulin signaling pathway: implications on the longevity of the long-lived Snell dwarf mouse.Mech Ageing Dev.2002; 123: 1245–1255.
56.
WeindruchR., SohalR.S.. Seminars in medicine of the Beth Israel Deaconess Medical Center: caloric intake and aging.N Engl J Med.1997; 337: 986–994.
57.
DirksA.J., LeeuwenburghC.. Caloric restriction in humans: potential pitfalls and health concerns.Mech Ageing Dev.2006; 127: 1–7. Epub 2005 Oct 13.
58.
BarzilaiN., GuptaG.. Interaction between aging and syndrome X: new insights on the pathophysiology of fat distribution.Ann N Y Acad Sci.1999; 892: 58–72.
59.
DominiciF.P., Arostegui DiazG., BartkeA.. Compensatory alterations of insulin signal transduction in liver of growth hormone receptor knockout mice.J Endocrinol.2000; 166: 579–590.
60.
DominiciF.P., HauckS., ArgentinoD.P.. Increased insulin sensitivity and upregulation of insulin receptor, insulin receptor substrate (ISR)-1 and IRS-2 in liver of Ames dwarf mice.J Endocrinol.2002; 173: 81–94.
61.
IkenoY., BronsonR.T., HubbardG.B.. Delayed occurrence of fatal neoplastic diseases in Ames dwarf mice: correlation to extended longevity.J Gerontol A Biol Sci Med Sci.2003; 58: 291–296.
62.
ChibaT., YamazaH., HigamiY.. Anti-aging effects of caloric restriction: involvement of neuroendocrine adaptation by peripheral signaling.Microsc Res Tech.2002; 59: 317–324.
63.
LaneM.A., TilmontE.M., De AngelisH.. Short-term calorie restriction improves disease-related markers in older male rhesus monkeys (Macaca mulatta).Mech Ageing Dev.2000; 112: 185–196.
64.
HolzenbergerM., DupondJ., DucosB.. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice.Nature.2003; 421: 182–187. Epub 2002 Dec 4.
65.
DilmanV.M.. Age-associated elevation of hypothalamic threshold to feedback control, and its role in development, aging and disease.Lancet.1971; 1: 1211–1219.
66.
BersteinL.M., KvatchevskayaJ.O., PoroshinaT.E.. Insulin resistance, its consequences for clinical course of the disease, and possibilities of correction in endometrial cancer.J Cancer Res Clin Oncol.2004; 130: 687–693.
67.
BersteinL.M.. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer.Cancer Lett.2005; 224: 203–212. Epub 2004 Dec 13.
68.
DilmanV.M., AnisimovV.N.. Effect of treatment with phenoformin, dyphenylhydantoin or L-dopa on life span and tumour incidence in C3H/Sn mice.Gerontology.1980; 26: 241–246.
69.
AnisimovV.N., SemenchenkoA.V., YashinAl. Insulin and longevity: antidiabetic biguanides as geroprotectors.Biogerontology.2003; 4: 297–307.
70.
AnisimovV.N., BersteinL.M., EgorminP.A.. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.Exp Gerontol.2005; 40: 685–693.
71.
AnisimovV.N., BersteinL.M., PopovichI.G.. Central and peripheral effects of insuling/IGF-1 signaling in aging and cancer: antidiabetic drugs as geroprotectors and anticarcinogens.Ann N Y Acad Sci.2005; 1057: 220–234.
72.
SpindlerS.R.. Use of microarray biomarkers to identify longevity therapeutics.Aging Cell.2006; 5: 39–50.
73.
AnisimovV.N.. Insulin/IGF-1 signaling pathway driving aging and cancer as a target for pharmacological intervention.Exp Gerontol.2003; 38: 1041–1049.
74.
SchneiderM.B., MatsuzakiH., HarorahJ.. Prevention of pancreatic cancer induction in hamsters by metformin.Gastroenterology.2001; 120: 1263–1270.
75.
DilmanV.M., AnisimovV.N.. Potentiation of antitumor effect of cyclophosphamide and hydrazine sulfate by treatment with the antidiabetic agent, 1-phenylethylbiguanide (phenformin).Cancer Lett.1979; 7: 357–361.
76.
EvansJ.M., DonnelyL.A., Emslie-SmithA.M.. Metformin and reduced risk of cancer in diabetic patients.BMJ.2005; 330: 1304–1305. Epub 2005 Apr 22.
77.
BowkerS.L., MajumdarS.R., VeugelersP.. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.Diabetes Care.2006; 29: 254–258.
78.
GargiuloP., CacceseD., PignatelliP.. Metformin decreases platelet superoxide anion production in diabetic patients.Diabetes Metab Res Rev.2002; 18: 156–159.
79.
LeeJ., ChanS.L., LaneM.A.. Phenformin suppresses calcium responses to glutamate and protects hippocampal neurons against excito-toxicity.Exp Neurol.2002; 175: 161–167.
80.
El-MirM.Y., NogueiraV., FontaineE.. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.J Biol Chem.2000; 275: 223–228.
81.
ZhouG., MyersR., LiY.. Role of AMP-activated protein kinase in mechanism of metformin action.J Clin Invest.2001; 108: 1167–1174.
82.
PaolissoG., AmatoL., EccellenteR.. Effect of metformin on food intake in obese subjects.Eur J Clin Invest.1998; 28: 441–446.
83.
Fruehwald-SchultesB., OltmannsK.M., ToschekB.. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men.Metabolism.2002; 51: 531–536.
84.
MickG.J., WangX., Ling FuC.. Inhibition of leptin secretion by insulin and metformin in cultured rat adipose tissue.Biochim Biophys Acta.2000; 1502: 426–432.
85.
von WangenheimK.H., PetersonH.P.. Control of cell proliferation by progress in differentiation: clues to mechanisms of aging, cancer causation and therapy.J Theor Biol.1998; 193: 663–678.
86.
ReyaT., MorrisonS.J., ClarkeM.F.. Stem cells, cancer, and cancer stem cells.Nature.2001; 414: 105–111.
87.
MoolgavkarS., KrewskiD., ZeiseL., eds. Quantitative Estimation and Prediction of Human Cancer Risk. IARC Scientific Publication No. 131. Lyon, France: International Agency for Research on Cancer; 1999.
88.
BerenblumI.. Sequential aspects of chemical carcinogenesis: skin. In: BeckerJ., ed. Cancer a Comprehensive Treatise.New York: Plenum Press; 1975: 323–344.
89.
Consensus Report. In: VanioH., MageeP.N., McGregorD., eds. Mechanisms of Carcinogenesis in Risk Identification. IARC Scientific Publication No.116. Lyon, France: International Agency for Research on Cancer; 1992.
90.
HanahanD., WeinbergR.A.. The hallmarks of cancer.Cell.2000; 100: 57–70.
